Loading...
Documents
-
Léa Rubira, Charlotte Donzé, Juliette Fouillet, Benjamin Algudo, Pierre Olivier Kotzki, et al.. [68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: thorough study of the automated radiolabeling reaction conditions. Applied Radiation and Isotopes, 2024, 206, pp.111211. ⟨10.1016/j.apradiso.2024.111211⟩. ⟨hal-04544439⟩
-
Céleste Souche, Juliette Fouillet, Léa Rubira, Charlotte Donzé, Charlotte Donzé, et al.. Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy. International Journal of Molecular Sciences, 2023, 25 (1), pp.462. ⟨10.3390/ijms25010462⟩. ⟨hal-04544442⟩
-
Tristan Martin, Anaïs Moyon, Cyril Fersing, Evan Terrier, Aude Gouillet, et al.. Have you looked for “stranger things” in your automated PET dose dispensing system? A process and operators qualification scheme. European Association of Nuclear Medicine, issuing body - EJNMMI radiopharmacy and chemistry, 2019, 4 (1), pp.11. ⟨10.1186/s41181-019-0061-8⟩. ⟨hal-04175661⟩
-
Regis Souche, Jean-Michel Fabre. Comment on: “Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy: a multicentre cohort study and meta-analysis”. Hepatobiliary Surgery and Nutrition, 2022, 11 (1), pp.94-96. ⟨10.21037/hbsn-22-2⟩. ⟨hal-04543736⟩
-
Morgan Michalet, Karl Bordeau, Marie Cantaloube, Simon Valdenaire, Pierre Debuire, et al.. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study. Frontiers in Oncology, 2022, 12, pp.842402. ⟨10.3389/fonc.2022.842402⟩. ⟨hal-04538122⟩
-
Esin Orhan, Carolina Velazquez, Imene Tabet, Lise Fenou, Geneviève Rodier, et al.. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. Cancer Letters, 2024, 589, pp.216820. ⟨10.1016/j.canlet.2024.216820⟩. ⟨hal-04535765⟩
-
Carolina Velazquez, Esin Orhan, Imene Tabet, Lise Fenou, Béatrice Orsetti, et al.. BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. Frontiers in Oncology, 2023, 13, pp.1125021. ⟨10.3389/fonc.2023.1125021⟩. ⟨hal-04275543⟩
-
Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
-
Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
-
Jean-Marc Classe, Gilles Dolivet, Serge Evrard, Gwenael Ferron, Fabrice Lécuru, et al.. Recommandations de la Société française de chirurgie oncologique (SFCO) pour l’organisation de la chirurgie oncologique durant l’épidémie de COVID-19. Bulletin du Cancer, 2020, 107 (5), pp.524-527. ⟨10.1016/j.bulcan.2020.03.010⟩. ⟨hal-02988833⟩
-
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩